2024-SABCS-Meeting-Preview - 4

Special sessions bring timely topics
to the 2024 SABCS®
F
our days
of new and notable
programming at the
2024 San Antonio Breast
Cancer Symposium®
will delve into essential
discussions for everyone
who is focused on breast
cancer and premalignant
breast disease, from
researchers and clinicians
to patients and other
advocates.
" I feel like that's what
makes the SABCS® special, "
said SABCS® Program
Director Kate Lathrop, MD,
of the Mays Cancer Center
at UT Health Science Center
San Antonio. " We try to
address the whole continuum
of breast cancer science,
treatment, and long-term
care. It's everything from
disparities to survivorship to
translational medicine. "
This year, the Symposium
will feature several new
offerings and cuttingedge
education sessions
designed to be impactful
and relevant for attendees
once they return home.
SEX, DRUGS,
AND ROCK AND ROLL
Sex, Drugs, Rock and Roll is
one of three special sessions
that will concurrently kick
off the symposium at noon
CST on Tuesday, December
10. This new session
features much more than its
4
eye-catching
title - presentations will
spotlight important topics
that may not always be
prominent in discussions
about breast cancer
treatment.
Speakers will address
supplement and cannabis
use, explore considerations
related to sexual health
and exercise, and examine
how alcohol intake affects
the risk of recurrence and
treatment outcomes. A
panel discussion will provide
additional perspectives from
breast cancer scientists and
a patient advocate.
" I think this will be a
popular session, " Dr. Lathrop
said. " It's really going to
focus on questions patients
ask us that we don't always
know the answer to or don't
know how much data there
are behind them. "
INSIGHTS FROM THE FDA
FDA Special Session:
New Drug Approvals, also
scheduled for noon on
Tuesday, will offer SABCS®
attendees the opportunity
to hear directly from experts
with the U.S. Food and
Drug Administration (FDA)
Office of Oncologic Diseases
about pertinent regulatory
decisions.
" The point of this session
is to go over the drugs that
were approved
this year, " Dr.
Lathrop said,
" and why they
were approved in
a specific manner,
whether that's
a certain indication, in a
certain time period during
the course of treatment, or
certain doses. "
SPOTLIGHT ON
PREVENTION
Breast cancer prevention
was a topic that organizers
wanted to emphasize
across the 2024 SABCS®
program, Dr. Lathrop said,
and multiple sessions
throughout the week will
address this timely subject.
Prevention Special
Session: Mechanisms
of Obesity Related Risk
for Breast Cancer and
Approaches to Risk
Reduction, at noon on
Tuesday, will look at three
unique angles: the lifestyle,
genetic, and epigenetic
interactions in predicting
the development of obesity
and response to calorie
restriction and physical
activity; achieving sufficient
fat loss and metabolic
improvement to reduce
cancer risk with newer
generation GLP-1 and GIP
receptor agonists; and
the impact of exercise
and pharmacotherapy for
weight loss.
At noon on Wednesday,
December 11, the session
Early Detection will feature
presentations on risk-based
screening in the average
population, novel imaging
modalities, and screening
for women categorized as
high-risk.
At 12:30 p.m. on Thursday,
December 12, The Future
of Cancer Genetics Is Here
will spotlight discussions on
risk prediction models.
Back-to-back sessions
on Friday, December 13,
will add further depth to
the conversation. New
Directions in Breast Cancer
Prevention at 12:30 p.m.
will highlight the current
state of prevention vaccines,
the potential for more
sophisticated biomarkerdriven
prevention strategies,
and improvements in
prevention-oriented clinical
trials. A debate session at
2 p.m. will highlight varying
views on whether all patients
should be offered universal
germline genetic testing. 
2024 SABCS®
| Meeting Preview
2024-SABCS-Meeting-Preview

Table of Contents for the Digital Edition of 2024-SABCS-Meeting-Preview
